Daniel Cho covers the business and financial dimensions of biotechnology and healthcare, with an emphasis on how investment trends reflect deeper shifts in innovation and risk. His reporting explores capital allocation, strategic deals, and market signals across the life sciences. At The Catalyst Brief, Daniel connects financial activity to scientific progress and policy developments to provide a more complete view of the industry.
148 articlesMostly Regulatory & Policy and Biopharmaceutical Industry
Biopharmaceutical IndustryMany scientists who become CEOs may unintentionally move away from their foundational scientific principles when managing commercial innovations. Embracing a disciplined, scientific approach in business strategies can prevent common pitfalls, attract crucial investment, and accelerate the delivery of transformative technologies to the market.
Daniel ChoFeb 19, 2026
Regulatory & PolicyFollowing the departure of Jim O’Neill, Jay Bhattacharya steps in as the latest acting CDC chief. This leadership change comes at a critical juncture, with implications for public health policies, agency direction, and the CDC's role in responding to emerging health issues.
Daniel ChoFeb 18, 2026
Biopharmaceutical IndustryHistorically known for collaborating in drug development, Ionis Pharmaceuticals charted a new course by bringing two medicines to market alone in 2025. Industry analysts are recognizing the company's strategic pivot and anticipate further progress in 2026.
Daniel ChoFeb 18, 2026
Regulatory & PolicyAs artificial intelligence rapidly becomes an essential tool in drug development and regulatory review, the Drug Information Association (DIA) is actively bridging the gap between high-level AI principles and everyday regulatory practices. This article explores DIA’s initiatives and their impact on streamlining regulatory processes while ensuring safety and efficacy in medical innovation.
Daniel ChoFeb 16, 2026
AI in Drug DiscoveryThe infusion of $40 million funding into Anterior marks a significant advancement in leveraging artificial intelligence to transform administrative processes in healthcare. By enabling near-instantaneous care approvals, this technology promises to alleviate clinician burdens and optimize payer operations.
Daniel ChoFeb 14, 2026
Biotech InnovationThe Mayo Clinic Platform offers a revealing perspective on the limitations of de-identified electronic health records (EHR) data, suggesting that extensive de-identification processes may diminish the data's practical value for pharma and research entities. This insight underscores the ongoing tension between patient privacy and the imperative for actionable, high-quality data in drug development.
Daniel ChoFeb 13, 2026
Biotech InnovationBridgeBio Pharma's recent clinical trial achievement with infigratinib marks a meaningful advancement in the treatment of achondroplasia. The drug demonstrated significant improvements in growth rates and body composition in children, offering hope to patients with this genetic condition. Regulatory pathways are now anticipated to proceed toward FDA filing within the year.
Daniel ChoFeb 12, 2026
Biopharmaceutical IndustryThe recent proof-of-concept clinical trial results for brepocitinib mark a pivotal milestone for Roivant’s rare disease pipeline. Licensed from Pfizer, this dual JAK1 and TYK2 inhibitor demonstrated promising outcomes in cutaneous sarcoidosis, an area of high unmet medical need with no FDA-approved therapies, positioning the drug on a path toward pivotal testing and potential blockbuster status.
Daniel ChoFeb 8, 2026
Regulatory & PolicyThe recent NFL Players Association-funded study on chronic traumatic encephalopathy (CTE) has sparked fierce criticism. A prominent scientist and NFL widow highlights concerns about the study's findings and implications, calling attention to the ongoing challenges of accurately understanding and addressing CTE among football players.
Daniel ChoFeb 7, 2026
Biopharmaceutical IndustryGSK's strategic decision to forgo developing GLP-1 drugs represents a distinct approach in the obesity treatment landscape. The company's focus on innovative therapies like its FGF21 analog efimosfermin alfa, particularly aimed at liver fibrosis, signals a nuanced understanding of obesity’s complex pathophysiology and its complications.
Daniel ChoFeb 4, 2026
Biopharmaceutical IndustryFacing mounting competition from new entrants and evolving market dynamics, Novo Nordisk has adjusted its 2026 financial outlook downward. The Danish pharmaceutical leader, known for its obesity drug Wegovy, is navigating a changing landscape that impacts its growth trajectory in the weight management sector.
Daniel ChoFeb 3, 2026
Healthcare InvestmentThe health technology landscape entered 2026 with vigor, seen through four notable funding announcements that signal robust investor confidence. These funding rounds underpin developments in digital health, telemedicine, and biotechnology, marking an exciting chapter for healthcare innovation and investment.
Daniel ChoJan 31, 2026